7 recruiting, 4 completed, 4 unknown, 1 terminated. 11 Phase 2, 5 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 11 | Recruiting 6, Completed 2, Unknown 2, Withdrawn 1 |
| Phase 1 | 5 | Recruiting 2, Terminated 1, Unknown 1, Withdrawn 1 |
| Phase 3 | 1 | Recruiting 1 |
Follow PARP inhibitor: new trials by email Literature Review of PARP inhibitor trials Research Report on PARP inhibitor
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| First in Human Study of SNV1521 With a RAS Inhibitor for People With Advanced Pancreatic Cancer SNV1521, daraxonrasib - Pancreatic Cancer, Pancreatic Acinar Carcinoma | Phase 1 | Recruiting | ParVation Therapeutics, Inc. | 40 | 2026-09-01 | 2026-10-27 |
| [18F]FTT Positron Emission Tomography for the Measurement of PARP Tumor Expression in Patients With Metastatic Breast Cancer Best Practice, Biopsy of Breast, Computed Tomography - Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Breast Carcinoma | Phase 1 / Phase 2 | Recruiting | University of Washington | 22 | 2026-02-26 | 2026-05-19 |
| An Open-Label, Bayesian Adaptive Phase II Clinical Study in HR+/HER2- Advanced Breast Cancer After Progression on Standard Therapy L-Ornithine L-Aspartate, CDK4/6 inhibitor, Fulvestrant - Breast Cancer | Phase 2 | Recruiting | Fudan University | 60 | 2025-09-25 | 2026-07-13 |
| PARP (Poly (ADP-ribose) Polymerase) Inhibitor With or Without Angiogenesis Inhibitor in Homologous Recombination Deficient Primary Ovarian Cancer, Fallopian-Tube Cancer, or Primary Peritoneal Cancer PARP inhibitor + Bevacizumab, PARP inhibitor - Ovarian Cancer, Fallopian Tube Cancers | Phase 2 / Phase 3 | Recruiting | N.N. Alexandrov National Cancer Centre | 120 | 2025-07-01 | 2026-03-16 |
| Precision Treatment of Recurrent/Metastatic Salivary Gland Carcinoma Guided by Molecular Typing Cohort 1 (HER2-positive, RC48-ADC), Cohort 2 (NTRK-fusion or NTRK-mutant), Cohort 3 (AR-positive, leuprolide + bicalutamide + abiraterone) - Salivary Gland Carcinoma, Precision Therapy | Phase 2 | Recruiting | Peking Union Medical College | 39 | 2023-08-15 | 2026-04-02 |
| Surgery Combined With Maintenance Targeted Therapy in the Treatment of Advanced Ovarian Cancer Primary debulking surgery, Neoadjuvant chemotherapy, PARP inhibitor - Ovarian Cancer, Fallopian Tube Cancer | Phase 2 | Recruiting | Shanghai Gynecologic Oncology Group | 220 | 2022-07-13 | 2025-02-10 |
| PD1 and PARP for Maintenance Therapy in NSLLC PD-1 inhibitor, PARP inhibitor - Lung Cancer | Phase 2 | Unknown | Tianjin Medical University Cancer Institute and Hospital | 52 | 2022-06-20 | 2022-05-26 |
| Homologous Recombination Deficiency in Chinese Ovarian Cancer Patients PARP inhibitor - Ovarian Cancer, HRD | Unknown | Xiaoxiang Chen | 100 | 2021-09-15 | 2021-09-14 | |
| Pancytopenia Related to PARP Inhibitors (PancytoRIB) PARP inhibitor - Cancer | Completed | University Hospital, Caen | 200 | 2021-02-07 | 2021-09-23 | |
| Neoadjuvant Intense Endocrine Therapy for High Risk and Locally Advanced Prostate Cancer ADT, Abiraterone Acetate, Prednisolone tablets - Neoadjuvant Therapy, High Risk Prostate Cancer | Phase 2 | Recruiting | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | 900 | 2020-02-01 | 2022-08-16 |
| Real World Data Analysis of PARP Inhibitors Use in Patients With Ovarian Cancer PARP inhibitor - Ovarian Cancer | Completed | Hellenic Cooperative Oncology Group | 180 | 2019-11-01 | 2026-10-19 | |
| Durvalumab and Olaparib in Metastatic or Recurrent Endometrial Cancer PARP inhibitor and Anti-PD-L1 - Endometrial Neoplasms, Uterine Neoplasms | Phase 2 | Unknown | Leiden University Medical Center | 55 | 2019-07-08 | 2021-04-01 |
| The Study of SHR7390 in Combination With SHR-1210 and SHR3162 in Patients With Advanced Solid Tumors SHR7390, SHR-1210, SHR3162 - Solid Tumor | Phase 1 | Terminated | Jiangsu HengRui Medicine Co., Ltd. | 31 | 2017-07-24 | 2022-09-01 |
| Study in Patients With SCLC of Veliparib in Combination With Topotecan veliparib, Topotecan - Small Cell Lung Cancer SCLC | Phase 1 | Unknown | Central European Society for Anticancer Drug Research | 30 | 2016-10-01 | 2021-01-27 |
| Combination of Carboplatin, Eribulin Mesylate, and E7449 in BRCA-Related Cancers Carboplatin, Eribulin, E7449 - Cancer of the Breast | Phase 1 / Phase 2 | Withdrawn | The University of Texas Health Science Center at San Antonio | 2015-04-01 | 2015-08-25 | |
| A Single-Arm Study Evaluating Carboplatin/Gemcitabine in Combination With BSI-201 in Patients With Platinum-Resistant Recurrent Ovarian Cancer BSI-201 - Ovarian Cancer | Phase 2 | Completed | Sanofi | 43 | 2009-12-01 | 2016-03-17 |
| A Single-Arm Study Evaluating Carboplatin/Gemcitabine in Combination With BSI-201 in Patients With Platinum-Sensitive Recurrent Ovarian Cancer BSI-201 - Ovarian Cancer | Phase 2 | Completed | Sanofi | 41 | 2009-12-01 | 2016-03-17 |
Ovarian Neoplasms (6) · Breast Neoplasms (3) · Neoplasms (3) · Fallopian Tube Neoplasms (2) · Hypersensitivity (2) · Recurrence (2) · Endometrial Neoplasms (1) · Kenny-Caffey syndrome, Type 1 (1) · Lung Neoplasms (1) · Pancreatic Neoplasms (1) · Parkinson Disease 4, Autosomal Dominant Lewy Body (1) · Salivary Gland Neoplasms (1) · Small Cell Lung Carcinoma (1) · Uterine Neoplasms (1)
Sanofi (2) · Central European Society for Anticancer Drug Research (1) · Fudan University (1) · Hellenic Cooperative Oncology Group (1) · Jiangsu HengRui Medicine Co., Ltd. (1) · Leiden University Medical Center (1) · N.N. Alexandrov National Cancer Centre (1) · ParVation Therapeutics, Inc. (1) · Peking Union Medical College (1) · Shanghai Gynecologic Oncology Group (1) · The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School (1) · The University of Texas Health Science Center at San Antonio (1) · Tianjin Medical University Cancer Institute and Hospital (1) · University Hospital, Caen (1) · University of Washington (1)
China (7) · United States (4) · Belarus (1) · France (1) · Germany (1) · Greece (1) · Netherlands (1)
Jennifer Specht, MD (1) · Jie Zhang (1) · Joachim von Pawel, MD (1) · Libing Xiang (1) · RuiHua Xu, MD, PhD (1) · Virginia Kaklamani (1) · Xiaoxiang Chen, MD,PhD (1)